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Abstract
Background: Chronic rhinosinusitis (CRS) is an inflammation of the nose and of
the paranasal sinuses. The involvement of the respiratory epithelium in the mech-
anisms of CRS is poorly understood.
Aims: Among proteins expressed by nasal epithelial cells in CRS, IL-19 may have
key functions. We here aimed to determine the expression and regulation of IL-19.
Methods: Nasal biopsies from normal subjects (n = 12), subjects with CRS but
without nasal polyps (NP) (CRSsNP, n = 12) and with CRS with NP (CRSwNP,
n = 15) were collected. Human Asthma Gene Array and real-time PCR were used
to evaluate gene expression, western blot analysis and immunohistochemistry for
protein expression. Results for IL-19 were confirmed by real-time PCR. The con-
stitutive and stimulated (LPS, TGF b) expression of IL-19 and cell proliferation
were evaluated in a nasal epithelial cell line (RPMI 2650).
Results: Human Asthma Gene Array showed an increased IL-19 gene expression
in NP from patients with CRS in comparison with normal subjects. Real-time
PCR confirmed the IL-19 mRNA up-regulation in patients with CRSwNP and
showed an up-regulation of IL-19, at lower extent, in patients with chronic rhi-
nosinusitis without nasal polyps (CRSsNP) in comparison with normal subjects.
Western blot analysis confirmed that IL-19 is increased also at protein level in
patients with CRSwNP in comparison with normal subjects. In NP, IL-19 is
highly expressed in the metaplastic nasal epithelium when compared to normal or
hyperplastic epithelium. LPS stimulation increased IL-19 expression, and recom-
binant IL-19 increased cell proliferation in nasal epithelial cells.
Conclusions: IL-19 is overexpressed in the epithelium in CRSwNP and increases
epithelial cell proliferation.
Chronic rhinosinusitis (CRS) is an inflammation of the nose
and of the paranasal sinuses, which may be differentiated in
CRS without (CRSsNP) and with nasal polyps (CRSwNP)
based on remodelling and inflammatory patterns (1, 2).
CRSwNP is mainly characterized by eosinophilic inflamma-
tion and prevalent helper T cell type(Th)-2 responses while
CRSsNP is characterized by neutrophilic inflammation and
prevalent Th1 responses (3). The aetiology and pathogenesis
of CRS are largely unknown, and abnormalities in host
response to external insults including allergens, fungi, bacte-
ria and virus have been suggested to underlie the persistence
of the inflammatory state (4). Among these, Staphylococcus
aureus may play an important role by releasing enterotoxins,
acting as superantigens and amplifying the Th2-biased
Abbreviations
CRS chronic rhinosinusitis; CRSwNP chronic rhinosinusitis with
nasal polyps; CRSsNP chronic rhinosinusitis without nasal polyps;
IL interleukin; NP nasal polyps.
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immune response (5). Histological features of CRSwNP
resemble that of asthmatic airways with end-stage polyps dis-
playing signs of Th2 inflammation characterized by infiltra-
tion with eosinophils, thickening of the basement membrane,
and hyperplasia of the epithelium and are strikingly reminis-
cent of the histopathology of severe asthmatic airways (6).
Patients with severe and/or uncontrolled asthma have more
severe nasal computed tomographic (CT) scan abnormalities
than other patients (7). Multiple mechanisms may contribute
to the increase in Th2 responses. In asthmatic patients,
IL-17A and IL-4/IL-13 synergistically up-regulate IL-19
expression in airway epithelium, which in turn induces the
expression of Th2 cytokines in activated T lymphocytes (8).
Nasal epithelium plays a crucial role in innate and adaptative
immune responses, and alterations in epithelial barrier func-
tion and host defence responses may contribute to CRS path-
ogenesis (9,10). The immune mechanisms promoting the
structural alterations in CRS are not well elucidated.
In the present study, based on a gene array, we focus on
IL-19 RNA and protein expression and regulation of its pro-
duction as a possible key cytokine in the regulation of Th2
responses in CRS with NP.
Materials and methods
Study population
Patients were recruited at the ENT departments of Palermo,
Italy, and of Ghent, Belgium. We selected subjects without
CRS (n = 12) (age, 18–48 year) and without allergic diseases
or asthma (controls), subjects with CRS but without NP
(CRSsNP) (n = 12) (age, 23–51 year) and subjects with CRS
and NP (CRSwNP) (n = 15) (age, 20–48 year) (11). The
study fulfilled the criteria of the Ethics Committee of both
hospitals and was in agreement with the Helsinki Declara-
tion. All subjects had given their written informed consent.
Further details are provided in the Supporting information.
Nasal biopsies
Nasal biopsies were collected from inferior turbinates or
from nasal polyps. For mRNA analyses, nasal biopsies were
immediately kept in RNA-latter and snap-frozen at 80°C.
For immunohistochemistry, nasal biopsies were fixed (10%
neutral buffer formalin) and embedded in paraffin wax. Some
nasal biopsies from CRSwNP were freshly processed to iso-
late nasal epithelial cells as previously described (12).
cDNA expression array
Total RNA was isolated from the samples using TriZol
reagent (Invitrogen, Carlsbad, CA, USA) (13), and RNA puri-
fication was performed with RNeasy Mini kit (Qiagen Inc,
Valencia, CA, USA). Human Asthma Gene Array, analysing
85 asthma related genes simultaneously (SuperArray Inc.,
Bethesda, MD, USA), was used to compare the gene expres-
sion profiles of the collected samples as previously described
(14). The averages of two GAPDH or four cyclophilin A spots
were used as positive controls and set as baseline values with
which the signal intensity of other spots was compared. Using
these normalized data, we compared the signal intensity from
the membranes using the GEarray analyzer program (Super-
Array Corp., http://www.superarray.com).
Real-time quantitative RT-PCR of IL-19
Real-time quantitative PCR of IL-19 transcript was carried
out on ABI PRISM 7900 HT Sequence Detection Systems
(Applied Biosystems, Foster City, CA, USA) using specific
FAM-labelled probe and primers (Assays on Demand;
Applied Biosystems). Relative quantitation of mRNA levels
was carried out with comparative CT method (2
DDCt) (15).
Western blot analysis
The expression of IL-19 was evaluated by western blot analy-
sis as previously described (16) using a goat polyclonal anti-
body anti-IL-19 (1 : 100) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Membranes were then stripped and incu-
bated with goat polyclonal anti-ß-actin (Sigma-Aldrich, St
Louis, MO, USA). Revelation was performed with an
enhanced chemiluminescence system (GE Healthcare, Chal-
font St. Giles, UK) followed by autoradiography. Negative
controls were performed without primary antibody or includ-
ing an isotype control antibody. Data are expressed as densi-
tometric arbitrary units by correction with the density of the
bands obtained for beta-actin.
Immunohistochemistry
Immunohistochemistry was performed using goat anti-human
IL-19 polyclonal antibody (Santa Cruz Biotechnology)
(1 : 50) or using mouse anti-human Ki67 monoclonal anti-
body (Clone MIB-1; Code n. M7240; Dako, Glostrup,
Denmark) (1 : 75). For IL-19 expression, the intensity and
percentage scores were multiplied to give a composite score
of 1–9 for each specimen as previously described (17) (further
details in the Supporting information). For the Ki67 expres-
sion, the percentage of Ki67-positive cells was assessed in
normal/hyperplastic and in metaplastic epithelium of nasal
polyps from CRSwNP subjects.
Immunofluorescence microscopy
Immunofluorescence staining was performed on tissue sec-
tions from CRSwNP subjects to evaluate the co-localization
of IL-19 and Ki67. Immunostainings were performed using
goat anti-human IL-19 polyclonal antibody (Santa Cruz
Biotechnology) (1 : 50) and mouse anti-human monoclonal
ki67 antibody (Clone MIB-1; Code n. M7240; Dako)
(1 : 75). Double labelling was performed using a secondary
fluorescein isothiocyanate-conjugated donkey anti-goat anti-
body and phycoerythrin (PE)-conjugated goat anti-mouse
antibody (Sigma-Aldrich) in the same section. Slides were
analysed by a fluorescence microscope (Axioscop 2; Zeiss,
Heidelberg, Germany) at 488 lambda for the green fluores-
cence and at 589–610 lambda for the red fluorescence.
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Nasal epithelial cell line
RPMI 2650, a nasal epithelial cell line was cultured with
endotoxin (LPS 1 and 10 lg/ml–24 h) (Sigma-Aldrich) for
assessing IL-19 expression and with recombinant IL-19 (r
IL-19) (200 ng/ml) (R&D Systems, Minneapolis, MN,
USA), herbimycin, a tyrosine kinase inhibitor (Sigma)
(2 lM) and Na orthovanadate, a tyrosine phosphatase
inhibitor (Sigma) (10 lM) (15), for 72 h for assessing cell
proliferation as previously described (18). The time point
was selected on the basis of preliminary experiments
(data not shown). At the end of stimulation, cells were
collected for assessing IL-19 expression and/or for cell
proliferation.
Expression of IL-19 and of ki67 in nasal epithelial cells
The IL-19 protein expression was assessed by western blot
(as mentioned previously) and by flow cytometry analysis.
The ki67 was assessed by flow cytometry analysis. RPMI
2650 cells and primary epithelial cells isolated from a
CRSwNP were used for these experiments. The expression of
IL-19 and of ki67 by flow cytometry was assessed in permea-
bilized cells. Data are expressed as percentage of positive
cells.
Cell proliferation
RPMI 2650 was stimulated with r IL-19 with/without herbi-
mycin and Na orthovanadate. Cell proliferation was assessed
using carboxyfluorescein succinimidyl ester (19) labelling
assay and by clonogenic assay (15). Further details are pro-
vided in the Supporting information.
Statistics
Data are expressed as median (25–75 percentiles). Kruskal–
Wallis test was performed for comparisons between patient
groups. A nonparametric Mann–Whitney test was applied as
the initial Kruskal–Wallis test was significant. The Spearman
test was used for correlations. Student’s paired t-test was
used for comparisons in RPMI cell line. P < 0.05 was
accepted as statistically significant.
Results
Demographic characteristics of the subjects
The demographic characteristics and the clinical evaluations
of the studied patients are shown in Table 1.
Increased expression of IL-19 mRNA in CRS with nasal
polyps by Human Asthma Gene Array
Human Asthma Gene Array, analysing 85 asthma related
genes simultaneously (Table S1 in the Supporting informa-
tion), showed an greater than fivefold increase in IL-19 in
CRSwNP in comparison with controls (Fig. 1A). No signifi-
cant differences were observed between CRSsNP and normal
controls (Fig. 1B,C).
Real-time PCR confirms the increased expression of IL-19
mRNA in CRS with nasal polyps
Real-time PCR confirmed that IL-19 mRNA was strongly
up-regulated in patients with CRSwNP and showed a signifi-
cant up-regulation of IL-19 mRNA, at lower extent, also in
the mucosa from inferior turbinate of patients with CRSsNP
in comparison with controls (Fig. 1D).
Increased expression of IL-19 protein in CRS with nasal
polyps.
Western blot analysis confirmed that IL-19 is increased also
at protein level in patients with CRSwNP in comparison with
controls (Fig. 2A,B). There was no significant trend in the
increase in IL-19 protein in CRSsNP.
Squamous metaplastic nasal epithelium shows higher
expression of IL-19 protein in CRS with nasal polyps
Immunohistochemistry, applied to identify which cells
express IL-19, showed that IL-19 is highly expressed in the
epithelium of CRSsNP and of CRSwNP in comparison with
controls (Fig. 3A). In the subepithelial compartment, mucous
glands mainly expressed IL-19. In CRSwNP, higher expres-
sion of IL-19 was observed in squamous metaplastic nasal
epithelium (score, 4–9) when compared to not metaplastic
nasal epithelium (normal or hyperplastic epithelium) (score, 1
–3) (Fig. 3B). Confirming what previously was reported (10),
basal hyperplasia and mucous cell hyperplasia were observed
in CRSwNP (see arrow and arrowhead in Fig. 3B). In
patients with CRSwNP, IL-19 expression was independent of
atopy as defined by a positive SPT (data not shown) or of
asthma.
Nasal epithelial cells constitutively express IL-19
The expression of IL-19 in nasal epithelium may be the result
of a paracrine or an autocrine mechanism. Nasal epithelial
cells constitutively express IL-19, suggesting that the presence
of IL-19 in the epithelium of the recruited subjects may rep-
resent also the effect of an autocrine production (Fig. 4).
LPS (1 and 10 lg/ml) increased the percentage of IL-19-posi-
tive cells (Fig. 4A) and the constitutive production of IL-19
(Fig. 4B) in nasal epithelial cells.
We next explored whether r IL-19 was able to alter cell
proliferation in nasal epithelial cells and whether cell prolifer-
ation was affected by herbimycin and by Na orthovanadate,
Table 1 Demographic characteristics of the subjects
Controls = 12 CRSsNP = 12 CRSw NP = 15
Gender (M/F) 5/7 7/5 7/8
Asthma 0/12 4/12 8/15
Atopy 0/12 5/12 7/15
CRSsNP, chronic rhinosinusitis without nasal polyps.
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Figure 1 Increased expression of IL-19 mRNA in chronic rhinosi-
nusitis (CRS) with nasal polyps by Human Asthma Gene Array.
Nasal biopsies were collected from controls (n = 3), from subjects
with chronic rhinosinusitis without nasal polyps (CRSsNP) (n = 3)
and from chronic rhinosinusitis with nasal polyps (CRSwNP)
(n = 3). Total RNA was extracted, and Human Asthma Gene Array
was used to compare the gene expression profiles of the collected
samples. (A) Representative analysis performed by the GEarray
analyzer program showing the differences in gene expression of a
control (group 1) and of a CRSwNP (group 2). (B) Representative
membranes from control, CRS and CRSwNP patients. (C) Densito-
metric analyses of multiple GEarray experiments (n = 3). *P < 0.05.
Individual values are shown. Horizontal bars represent median val-
ues. (D) IL-19 m-RNA expression was also assessed by real-time
PCR in controls (n = 12), CRSsNP (n = 10) and CRSwNP (n = 10).
GAPDH gene expression was used as endogenous control for nor-
malization. Relative quantitation of mRNA was carried out with
comparative CT method. Individual values are shown. Horizontal
bars represent median values. * P < 0.002 vs controls; **
P < 0.002 vs CRS.
A B
Figure 2 Increased expression of IL-19 protein in chronic rhi-
nosinusitis (CRS) with nasal polyps by western blot analysis.
Nasal biopsies were collected from controls (n = 12), from
CRSsNP (n = 12) and from CRSwNP (n = 15). Total proteins
were extracted and analysed for IL-19 expression by western
blot analysis. Membranes were then stripped and incubated
with goat polyclonal anti-ß-actin. (A) Densitometric analysis of
IL-19 expression. Signals corresponding to IL-19 on the various
western blots were semiquantified by densitometric scanning,
normalized and expressed after correction with the density of
the band obtained for b-actin. Individual values are shown. Hori-
zontal bars represent median values. * P < 0.05. (B) Represen-
tative western blot analysis for IL-19 expression from a control,
a CRS and a CRSwNP.
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an inhibitor and an activator of tyrosine kinases, respectively.
Recombinant IL-19 alone and with Na orthovanadate
increased while herbimycin reduced the IL19-induced cell
proliferation (Fig. 4C,D).
Squamous metaplastic nasal epithelium shows higher
expression of Ki67 protein in CRS with nasal polyps
We finally investigated whether in the squamous metaplastic
epithelium, a deregulated expression of Ki67, a marker well
correlated with altered cell proliferation (20), occurred. The
percentage of Ki67-positive cells was significantly higher in
the metaplastic epithelium than in normal epithelium of nasal
polyps from CRSwNP (Fig. 5A). Flow cytometry (Fig. 5B)
in primary nasal epithelial cells from CRSwNP and immuno-
fluorescence in CRSwNP samples (Fig. 5C–E) showed that
Ki67 co-localized with IL-19 in nasal polyps.
Discussion
This study provides compelling evidence on the role of IL-19
in patients with CRSwNP. We have demonstrated that IL-19
induces nasal cell proliferation, is up-regulated at both
mRNA and protein levels and is highly expressed by the
squamous metaplastic epithelium of nasal polyps where an
increased expression of Ki67 occurs.
CRS is an inflammatory disease with distinct cytokine and
remodelling patterns. CRSwNP is characterized by a Th2-
skewed eosinophilic inflammation, whereas CRSsNP repre-
sents a predominant Th1 milieu. CRS severely affects
patients’ quality of life and complicates inflammation in adja-
cent organs and worsens associated diseases including asthma
(21). On the basis of the ‘one-airway hypothesis’, we initially
approached this study using an Asthma Gene Array to
explore the presence, in nasal compartment, of asthma like
gene expression alterations. Asthma gene Array demon-
strated that IL-19 is up-regulated, and real-time PCR analy-
sis confirmed that IL-19 gene expression was increased in
CRSwNP in comparison with normal subjects. Furthermore,
IL-19 protein expression was increased in the epithelium of
CRSwNP in comparison with normal subjects.
The genes encoding IL-19 and IL-20 cluster into the geno-
mic IL-10 region on human chromosome 1 (22). Microarray
technology and an immunohistochemical survey with an anti-
IL-19 antibody to examine the expression of IL-19 in healthy
and neoplastic tissues demonstrated that IL-19 protein was
positively stained in healthy lung tissue by epithelial cells,
endothelial cells and macrophages (23).
A
B
Figure 3 Higher expression of IL-19 protein in nasal epithelium
of chronic rhinosinusitis (CRS) with nasal polyps. IL-19 expression
was assessed by immunohistochemistry in controls (n = 12),
CRSsNP (n = 12) and CRSwNP (n = 15). Negative controls were
performed using rabbit immunoglobulins negative control. (A)
Representative negative control and representative immunostain-
ing (red stain) in a control, a CRSsNP and a CRSwNP at 2009
and at 4009 magnification. (B) The expression of IL-19 was
assessed in metaplastic and in not metaplastic (normal and
hyperplastic) epithelium of CRSwNP (n = 15). A composite score
was used to evaluate IL-19 expression. At the bottom of the
table, representative immunostainings are shown. Arrow points
to mucous cell hyperplasia while arrowhead points to basal cell
hyperplasia.
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There are limited comprehensive surveys of IL-19 expres-
sion in nasal human tissue or nasal cell types, and only few
biological functions and clinical implications of IL-19 are
known. It has been previously demonstrated that IL-19
down-regulates IL-4-induced eotaxin production in human
nasal fibroblasts from patients with allergic rhinitis, (24) but
no study specifically investigates the role of IL-19 in nasal
epithelium and in CRSwNP.
The synthesis of IL-19 is a tightly regulated mechanism.
In the present study, for the first time, a relevant increased
expression of IL-19 in nasal epithelial cells was observed
after LPS stimulation. In this regard, it has been demon-
strated that TLR4 signalling pathway, after LPS stimula-
tion, activates MyD88 and in turn induces Il-19 expression
in monocyte cultures (25,26). Moreover, it has recently been
demonstrated that nasal epithelial cells stimulated with en-
terotoxins B from Staphylococcus aureus release chemokines
including IL-8 and IP-10 (27) (Huvenne Allergy 2010).
Future studies are needed to clarify whether enterotoxins B
from S. aureus or Th2 cytokines (IL-4, IL-13) are able to
induce IL-19 expression/release. The increased levels of IL-
19 in CRSwNP may actively contribute to amplify the
inflammatory responses in these patients. IL-19, produced
by synovial cells, promotes joint inflammation in rheuma-
toid arthritis by inducing IL-6 production and decreasing
synovial cell apoptosis (28). IL-6 activates Th17 cells and
regulates the response of B lymphocytes and of regulatory
T cells. Consistently, in CRSwNP compared with controls,
IL-6 and IL-6 receptor (29) are increased while Foxp3
mRNA, a transcription factor, typically associated with T
regulatory activities was reduced (30,31). Furthermore, the
increased release of IL-19 may alter the balance of Th1 and
Th2 cells in favour of Th2 cells because this cytokine up-
regulates IL-4 and down-regulates interferon-c (32,33). In
bronchial asthma, a disease associated with increased Th2
responses, IL-19 levels are elevated three- to fourfold (33).
High IL-19 levels correlate with high IL-4 and IL-13 levels,
and epithelial cells in the airway of human asthma and
patients with chronic obstructive pulmonary disease are rich
in IL-19 (34). Accordingly, in CRSwNP, IL-5, IL-13 and
GATA-3, typically associated with Th2 responses, are
increased (35), and here, we demonstrated that in these
patients also IL-19 expression is increased. A positive feed-
back between the Th2 and IL-19 in asthma has been dem-
onstrated because bronchial epithelial cells stimulated by




Figure 4 IL-19 expression and cell proliferation in nasal epithelial
cells. Flow cytometric analysis (A) and western blot analysis (B)
were used for assessing IL-19 expression in a nasal epithelial
cell line (RPMI 2650) without or with LPS (1 and 10 lg/ml) stim-
ulation. (A) Representative histograms of a flow cytometric analy-
sis showing on the left the negative control using goat
immunoglobulins negative control, and on the right, the expres-
sion of IL-19 in the absence and in the presence of stimuli. (B)
Total proteins were extracted and analysed for IL-19 expression
by western blot analysis. Membranes were then stripped and
incubated with goat polyclonal anti-ß-actin. Representative wes-
tern blot analysis is shown. Nasal epithelial cell line (RPMI 2650)
was cultured with or without r IL-19 (200 ng/ml)and with IL-19
and herbimycin and Na orthovanadate. Cell proliferation was
assessed using carboxyfluorescein succinimidyl ester (CFSE) by
means of flow cytometry (C) and by clonogenic assay (D) (see
Materials and Methods for details). (A) Means ± SD of n = 3
experiments. *P < 0.05 paired t-test. At the bottom of the panel
A, one representative experiment is shown. (B) Means ± SD of
n = 3 experiments. *P < 0.05 paired t-test.
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presence of a similar mechanism also in patients with
CRSwNP may be supposed.
In addition, the increased levels of IL-19 may alter the pro-
liferation and the differentiation of the nasal epithelium in
CRSwNP. In psoriatic skin, IL-19 induces a gene expression
profile consistent with inflammatory responses, wound heal-
ing re-epithelialization and altered epithelial differentiation
(36). Epithelial damage and aberrant tissue remodelling are
common features of CRSwNP. Features of nasal remodelling
may be considered: squamous metaplasia, basement mem-
brane thickening, collagen deposition, hyperplasia of mucous
glands and goblet cells (37). Here, squamous metaplastic
nasal epithelium showed higher expression of IL-19 protein.
Nasal epithelial cells from patients with nasal polyps demon-
strated faster growth rates, and VEGF regulates nasal epithe-
lial cell proliferation because exposure of cells to blocking
antibodies against VEGF resulted in the inhibition of cell
growth (38). IL-19 specifically activated an intracellular sig-
nal and induced proliferation in oral cancer cells (23). The
binding of IL-19 to its receptor complex activates, as main
pathways, the tyrosine phosphorylation and the signal trans-
ducers and activators of transcription (STAT) pathways,
notably STAT1 and STAT3 (26,39,40). In the present study,
IL-19 increased nasal epithelial cell proliferation, and herbi-
mycin, a tyrosine kinase inhibitor, reduced IL-19-induced
nasal epithelial cell proliferation, suggesting that the prolifer-
ative role of IL-19 in nasal epithelial cells is mediated by
tyrosine phosphorylation events. Furthermore, IL-19 maxi-
mally activates tyrosine phosphorylation because the presence
of Na orthovanadate, a phosphotyrosine phosphatases inhibi-
tor, did not further increase cell proliferation. Finally, squa-
mous metaplastic nasal epithelium and primary nasal
epithelial cells from patients with CRSwNP highly co-
expressed IL-19 and Ki67. Ki67 is vital for cell proliferation,
and patients with CRSwNP and higher Ki67 planoepithelial
metaplasia are the subgroup with eosinophilic infiltrations
(41). Additional studies are needed to clarify the role of IL-




Figure 5 Squamous metaplastic nasal epithelium showed higher
expression of Ki67 protein in chronic rhinosinusitis (CRS) with
nasal polyps. (A) Immunohistochemistry was performed for
assessing Ki67 expression in nasal biopsies collected from
CRSwNP patients (n = 15). (B) Flow cytometry was performed for
assessing the expression of Ki67 and IL-19 on nasal epithelial
cells isolated from CRSwNP. A representative experiment is
shown. (C–E) Immunofluorescence was performed for assessing
Ki67 (red fluorescence) and IL-19 (green fluorescence) expression
in nasal biopsies collected from patients with CRS and NP
(CRSwNP) (n = 3). A representative experiment is shown. (C) Sin-
gle immunofluorescence for Ki67. (D) Single immunofluorescence
for IL-19. (E) Merged immunofluorescence for IL-19 and Ki67. For
single ki67 and IL-19 and for double ki67/IL-19, a particular from a
higher magnification is shown. See Materials and Methods for
details.
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